Literature DB >> 19555805

Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known.

Martijn S van Noorden1, Lieselotte C A M van Dongen, Frans G Zitman, Ton A C M Vergouwen.   

Abstract

Gamma-hydroxybutyrate (GHB) is an endogenous inhibitory neurotransmitter and anesthetic agent that is being abused as a 'club drug.' Withdrawal symptoms after cessation of GHB use are common and depend on the intensity of use. However, GHB withdrawal syndrome and delirium are unfamiliar to most psychiatrists, probably due to the fact that neither textbooks nor guidelines cover the subject. The GHB withdrawal syndrome may have a fulminant course that progresses to delirium. In those severe cases, admission to a general hospital and involvement of a psychiatrist become necessary. We present two cases of severe GHB withdrawal delirium, provide an overview of the literature and conclude with treatment recommendations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19555805     DOI: 10.1016/j.genhosppsych.2008.11.001

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  6 in total

1.  Behavioral effects of gamma-hydroxybutyrate in humans.

Authors:  Alison Oliveto; William Brooks Gentry; Rhonda Pruzinsky; Kishorchandra Gonsai; Thomas R Kosten; Bridget Martell; James Poling
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

Review 2.  Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.

Authors:  Rama M Kamal; Martijn S van Noorden; Wim Wannet; Harmen Beurmanjer; Boukje A G Dijkstra; Arnt Schellekens
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

3.  [Course and complications of GHB detoxification treatment: a 1-year case series].

Authors:  Peter Neu
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

Review 4.  Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.

Authors:  Enrico Marinelli; Renata Beck; Antonio Malvasi; Alfredo Fabrizio Lo Faro; Simona Zaami
Journal:  Arh Hig Rada Toksikol       Date:  2020-03-01       Impact factor: 1.948

5.  Severe illicit gamma-hydroxybutyric acid withdrawal in a pregnant woman: what to do?

Authors:  J C van Mechelen; Bag Dijkstra; Acm Vergouwen
Journal:  BMJ Case Rep       Date:  2019-12-02

6.  Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial.

Authors:  Anne Lingford-Hughes; Yash Patel; Owen Bowden-Jones; Mike J Crawford; Paul I Dargan; Fabiana Gordon; Steve Parrott; Tim Weaver; David M Wood
Journal:  Trials       Date:  2016-09-27       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.